---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-115296"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:18:38.076412+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents reports Q3 product revenue $8.6M (+11% YoY); net loss narrows to $2.3M

## Summary
- Product revenue $8.6M (+11% YoY); total revenue $9.4M; net loss $2.3M ($0.04/sh) vs $9.2M loss in Q3 2023.
- Product gross margins fell to 61% from 72% due to production slowdown and manufacturing issue now resolved.
- Adjusted EBITDA loss improved to $3.6M from $5.6M in Q3 2023; cash $12.2M at quarter-end vs $14.9M Q2 2024.
- DrugSorb-ATR De Novo application submitted to FDA Sep 27, accepted for review Oct 22; eligible for priority review.
- Received MDSAP certification Nov 1; submitted MDL application to Health Canada Nov 1.

## SEC filing metadata
- accession: 0001104659-24-115296
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465924115296/0001104659-24-115296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465924115296/tm2427790d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-115296
- JSON: https://secwatch.observer/filing/0001104659-24-115296.json
- Plain text: https://secwatch.observer/filing/0001104659-24-115296.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.